Edwards Lifesciences (0REN) Share Forecast & Price Target
0REN Analyst Ratings
Strong Buy
10Buy1Hold0Sell
Based on 11 analysts giving stock ratings to Edwards Lifesciences in the past 3 months
0REN Stock 12 Month Forecast
Average Price Target
CHF 86.27▲(0.00% Upside)Based on 11 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is CHF 86.27 with a high forecast of CHF 90.73 and a low forecast of CHF 70.11. The average price target represents a ― change from the last price of ―.
Highest Price TargetHighestCHF 90.73Average Price TargetCHF 86.27Lowest Price TargetLowestCHF 70.11
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Joanne Wuensch | Citi | CHF 87.43→CHF 90.73 | buy | ― | Reiterated | 11/01/26 | ||
| Josh Jennings | TD Cowen | CHF 85.78 | buy | ― | Reiterated | 10/27/26 | ||
| Mike Kratky | Leerink Partners | CHF 82.48→CHF 83.31 | buy | ― | Reiterated | 10/15/26 | ||
| Marie Thibault | BTIG | CHF 90.73 | buy | ― | Reiterated | 10/09/26 | ||
| Christopher Pasquale | Barclays | CHF 90.73 | buy | ― | Initiated | 10/07/26 | ||
| Patrick Wood | UBS | CHF 90.73 | buy | ― | Reiterated | 10/07/26 | ||
| Kendall Au | RBC Capital | CHF 90.73 | buy | ― | Reiterated | 10/01/26 | ||
| Adam Maeder | Piper Sandler | CHF 83.31 | buy | ― | Reiterated | 09/21/26 | ||
| Matthew Taylor | Jefferies | CHF 86.60 | buy | ― | Reiterated | 09/11/26 | ||
| Brandon Vazquez | William Blair | ― | buy | ― | Reiterated | 09/10/26 | ||
| William Plovanic | Canaccord Genuity | CHF 70.11 | hold | ― | Reiterated | 08/03/26 | ||
| Robbie Marcus | J.P. Morgan | CHF 86.60 | buy | ― | Reiterated | 07/28/26 | ||
| Richard Newitter | Truist Financial | CHF 78.36 | hold | ― | Reiterated | 07/24/26 | ||
| Suraj Kalia | Oppenheimer | ― | hold | ― | Reiterated | 07/24/26 | ||
| Rick Wise | Stifel Nicolaus | CHF 90.73 | buy | ― | Reiterated | 07/24/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Joanne Wuensch | 11/01/26 | CHF 87.43→CHF 90.73 | buy | ― | Reiterated | Citi | ||
| Josh Jennings | 10/27/26 | CHF 85.78 | buy | ― | Reiterated | TD Cowen | ||
| Mike Kratky | 10/15/26 | CHF 82.48→CHF 83.31 | buy | ― | Reiterated | Leerink Partners | ||
| Marie Thibault | 10/09/26 | CHF 90.73 | buy | ― | Reiterated | BTIG | ||
| Christopher Pasquale | 10/07/26 | CHF 90.73 | buy | ― | Initiated | Barclays | ||
| Patrick Wood | 10/07/26 | CHF 90.73 | buy | ― | Reiterated | UBS | ||
| Kendall Au | 10/01/26 | CHF 90.73 | buy | ― | Reiterated | RBC Capital | ||
| Adam Maeder | 09/21/26 | CHF 83.31 | buy | ― | Reiterated | Piper Sandler | ||
| Matthew Taylor | 09/11/26 | CHF 86.60 | buy | ― | Reiterated | Jefferies | ||
| Brandon Vazquez | 09/10/26 | ― | buy | ― | Reiterated | William Blair | ||
| William Plovanic | 08/03/26 | CHF 70.11 | hold | ― | Reiterated | Canaccord Genuity | ||
| Robbie Marcus | 07/28/26 | CHF 86.60 | buy | ― | Reiterated | J.P. Morgan | ||
| Richard Newitter | 07/24/26 | CHF 78.36 | hold | ― | Reiterated | Truist Financial | ||
| Suraj Kalia | 07/24/26 | ― | hold | ― | Reiterated | Oppenheimer | ||
| Rick Wise | 07/24/26 | CHF 90.73 | buy | ― | Reiterated | Stifel Nicolaus |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Edwards Lifesciences
3 Months
Success Rate19/29 ratings generated profit
66%
Average Return
+1.62%
Copying Adam Maeder's trades and holding each position for 3 Months would result in 65.52% of your transactions generating a profit, with an average return of +1.62% per trade.
1 Year
Success Rate11/13 ratings generated profit
85%
Average Return
+3.82%
Copying Travis Steed's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +3.82% per trade.
2 Years
Success Rate11/13 ratings generated profit
85%
Average Return
+6.85%
Copying Travis Steed's trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +6.85% per trade.
0REN Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 39 | 34 | 25 | 17 | 16 |
| Hold | 6 | 7 | 5 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 45 | 41 | 30 | 18 | 16 |
In the current month, 0REN has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0REN average Analyst price target in the past 3 months is 86.27.
0REN Financial Forecast
HighCHF 0.64
ConsensusCHF 0.61
LowCHF 0.59
0REN Earnings Forecast
Next quarter’s earnings estimate for 0REN is CHF 0.61 with a range of CHF 0.59 to CHF 0.64. The previous quarter’s EPS was CHF 0.64. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF 1.41B
ConsensusCHF 1.38B
LowCHF 1.36B
0REN Sales Forecast
Next quarter’s sales forecast for 0REN is CHF 1.38B with a range of CHF 1.36B to CHF 1.41B. The previous quarter’s sales results were CHF 1.44B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0REN Stock Forecast FAQ
What is GB:0REN’s average 12-month price target, according to analysts?
Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is CHF86.27.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Edwards Lifesciences a Buy, Sell or Hold?
Edwards Lifesciences has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
What is Edwards Lifesciences’s share price target?
The average share price target for Edwards Lifesciences is CHF86.27. This is based on 11 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF90.73, and the lowest forecast is CHF70.11. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about Edwards Lifesciences?
Edwards Lifesciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of Edwards Lifesciences?
To buy shares of GB:0REN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
